Prioritize Advanced Therapies in Crohn Disease

March 2026

The spotlight is on more up-front use of advanced therapies in moderate to severe Crohn disease...due to updated guidelines.

Previous guidelines suggested early use of biologics, with or withOUT immunomodulators (azathioprine, etc).

Now, guidelines are more streamlined, suggesting up-front use of “advanced therapies”...including the newer interleukin (IL)-23 antagonists risankizumab (Skyrizi), guselkumab (Tremfya), and mirikizumab (Omvoh).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote